*
on a scale of 1 – 4, with 1 being not confident and 4 being very confident
1234
Aldosterone/mineralocorticoid receptor antagonist (e.g. spironolactone)
Angiotensin-converting enzyme (ACE) inhibitors (e.g. enalapril)
Angiotensin receptor blockers (ARBs) (e.g. valsartan)
Angiotensin receptor/neprilysin inhibitors (ARNIs) (e.g. sacubitril/valsartan)
Beta-blockers (e.g. atenolol)
If (“funny”) current inhibitors (e.g. ivabradine)
*
*
*
*
*
Not significant at allSomewhat significantModerately SignificantVery significant
Concerns over potential short term adverse events (e.g. angioedema, hypotension)
Cost of therapy/coverage challenges
Lack of evidence regarding long-term adverse events
Patient unwillingness to switch therapies
Uncertainty regarding appropriate dosing/dose titration
Uncertainty regarding efficacy data
Uncertainty regarding who is likely to benefit
*
(on a scale of 1 – 4, with 1 being not confident and 4 being very confident
1234
Determining appropriate dosing/dose titration
Determining patient eligibility
Evaluating available efficacy data
Obtaining insurance coverage/reimbursement
Recognizing and managing adverse events

If you are interested in participating in the raffle for a $100 Amazon gift card, please fill out the following: